Mesenkia Therapeutics is pleased to announce that its US patent application IP001 has received a Notice of Allowance covering novel HVEM antagonistic single domain antibodies.
A Notice of Allowance means that the application has been approved for grant by the United States Patent and Trademark Office (USPTO), subject to the completion of the remaining administrative requirements.
The allowance represents an important milestone for Mesenkia’s intellectual property portfolio and supports the protection of the company’s innovation in the United States.
Mesenkia Therapeutics continues to build and strengthen its intellectual property portfolio in support of its research and development activities.
